Startup Showcase: Autolomous Industries – Revolutionizing Advanced Therapies Manufacturing

1 min read

Autolomous Industries is an innovative biotechnology company located in London that specializes in manufacturing pragmatic digital solutions for cell and gene therapy. The company’s flagship software platform, autoloMATE®, is a cloud-native enterprise-level software platform designed to provide end-to-end solutions for advanced therapies/vector/CGT manufacturing activities, focusing on the manufacturing process itself while seeking to integrate with other support systems. In this article, we’ll take a closer look at Autolomous and how it’s revolutionizing the advanced therapies manufacturing industry.

The Power of autoloMATE®: Streamlining Cell and Gene Therapy Manufacturing Processes

The market for cell and gene therapies is growing rapidly, and it presents unique manufacturing challenges that require new innovative solutions. Autolomous’ flagship software platform, autoloMATE®, is designed to meet these challenges head-on by offering advanced solutions that streamline the entire manufacturing process. This platform enables resource scheduling, management of electronic batch records, insights reporting, as well as review and release activities, all in one place. AutoloMATE® is flexible and can be configured to meet the needs of unique workflows, whether it’s a small biotech startup or a large pharmaceutical company.

ISO Certifications: A Mark of Quality and Security

Autolomous Industries is committed to providing its clients with only the highest quality digital solutions that meet security standards. That’s why the company has achieved ISO certifications across several standards – ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management). These certifications demonstrate Autolomous’ commitment to quality, data security, environmental protection, and continuous improvement.

Read more from UKT News:  Startup Showcase: Clariti AI - Revolutionizing Retail Banking with SaaS-Powered Pricing Optimization

Compliance with FDA, EMA, and MHRA Regulations

AutoloMATE® has been designed to comply with US FDA, EU EMA & UK MHRA guidance and aligns with the GAMP5 methodology. This ensures that Autolomous’ software is developed and maintained in a manner that meets the highest standards for pharmaceuticals, medical devices, and biologics. Compliance with these regulations is necessary to ensure patient safety, product quality, and reputation.

Conclusion: Digitized Solutions for Advanced Therapies Manufacturing

Autolomous Industries is pioneering the development of digitized solutions for advanced therapies manufacturing. The platform offers customized workflow solutions to address challenges in the manufacturing process that were traditionally difficult to manage. The company’s commitment to quality and security is evident through their ISO certifications and dedication to regulatory compliance. If you’re a biotech or pharma company looking to streamline your manufacturing process, Autolomous Industries and autoloMATE® are the solutions you need.

Website: https://autolomous.com/
Twitter: https://twitter.com/autolomous
Facebook: https://www.facebook.com/autolomous/
LinkedIn: https://www.linkedin.com/company/autolomous


Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.

Read more from UKT News:  Startup Showcase: Flyer One Ventures - Investing in the Future-Proof Startups from CEE Region

UKT News

UKT.news is a media platform owned by Unstructured Media, providing the latest news and insights on UK technology and startup scenes. The website offers readers with daily updates on the latest industry developments, as well as featuring exciting startups and advertising opportunities.

Leave a Reply

Your email address will not be published.